ZURICH — The Swiss stock market closed slightly higher on Tuesday, but the gain was narrow. The Swiss Market Index (SMI) was held up almost entirely by Novartis, the pharma heavyweight whose rally offset broader weakness among blue-chip names.
The clear majority of SMI constituents finished in the red. Investors remained cautious as persistent inflation concerns kept a lid on buying appetite. Bond yields have climbed sharply across global markets, adding to the climate of wariness around equities.
The day's split performance underscored a market divided between sector-specific strength and overarching macro prudence. While Novartis benefited from its own positive dynamics, the broader trend reflected growing investor scrutiny of how sustained higher interest rates could dampen growth outlooks and compress valuations.
Traders will be watching closely whether the defensive tilt toward pharmaceutical names can persist if rate anxieties intensify, or whether Novartis's outperformance is simply a rotation into quality amid uncertainty rather than a signal of deeper bullish conviction in Swiss equities as a whole.
